Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : RETA save search
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and Provides an Update on Clinical Development Programs
Published: 2022-02-28 (Crawled : 12:30) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -11.98%
H: 43.04%
C: 42.35%
als financial results ces program results
Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia
Published: 2023-02-28 (Crawled : 00:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.49%
H: 25.61%
C: 0.55%
fda pharmaceuticals drug approval friedreich’s ataxia
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
Published: 2023-11-22 (Crawled : 15:00) - biospace.com/
CNSP | News | $0.21 5.48% 0.95% 120K
|
Health Technology
|
| O: 3.35%
H: 25.0%
C: 4.17%
berubicin ongoing pharmaceuticals study
Reata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
Published: 2022-11-08 (Crawled : 12:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 3.15%
H: 18.92%
C: 11.92%
financial update results
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
Published: 2023-10-11 (Crawled : 13:00) - biospace.com/
CNSP | News | $0.21 5.48% 0.95% 120K
|
Health Technology
|
| O: -2.8%
H: 18.26%
C: 13.46%
rapid berubicin treatment ongoing glioblastoma study
Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
Published: 2022-05-10 (Crawled : 12:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 6.37%
H: 14.09%
C: 10.85%
results
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Faraday Future Intelligent Electric, Inc. f/k/a Property Solutions Acquisition Corp. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FFIE, FFIEW, PSAC, PSACW, PSACU
Published: 2022-01-30 (Crawled : 20:20) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 1.0%
H: 13.68%
C: 11.81%
acquisition intel acquisition corp deadline
Reata Pharmaceuticals Initiates Rolling Submission of New Drug Application with U.S. FDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
Published: 2022-01-31 (Crawled : 15:30) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 1.0%
H: 13.68%
C: 11.81%
new drug treatment fda als application drug one submission friedreich's ataxia friedreich’s ataxia
Reata Pharmaceuticals, Inc. to Report Third Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on November 8, 2022
Published: 2022-10-31 (Crawled : 00:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.4%
H: 11.31%
C: 8.42%
report financial update results
Reata Announces that The FDA Has Asked The Company to Request a Pre-NDA Meeting for Omaveloxolone for the Treatment of Friedreich’s Ataxia
Published: 2021-05-19 (Crawled : 11:00) - globenewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 13.45%
H: 9.49%
C: 9.11%
treatment fda friedreich's ataxia friedreich’s ataxia
CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin
Published: 2021-05-19 (Crawled : 15:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 13.45%
H: 9.49%
C: 9.11%
CNSP | News | $0.21 5.48% 0.95% 120K
|
Health Technology
|
| O: 0.0%
H: 3.19%
C: -1.06%
berubicin potential enroll
CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2022-09-28 (Crawled : 13:20) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 2.2%
H: 9.44%
C: 6.58%
CNSP | News | $0.21 5.48% 0.95% 120K
|
Health Technology
|
| O: -4.79%
H: 9.94%
C: 7.79%
treatment europe ongoing pharmaceuticals global trial berubicin
Over 100 Patients Now Enrolled in CNS Pharmaceuticals’ (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-04-10 (Crawled : 16:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.23%
H: 1.81%
C: 1.25%
CNSP | News | $0.21 5.48% 0.95% 120K
|
Health Technology
|
| O: -4.79%
H: 8.16%
C: 4.9%
berubicin treatment 100 glioblastoma study
CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-06 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.09%
H: 1.8%
C: 0.45%
CNSP | News | $0.21 5.48% 0.95% 120K
|
Health Technology
|
| O: 5.16%
H: 7.69%
C: 6.16%
treatment approval berubicin potential glioblastoma
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2024-01-17 (Crawled : 14:30) - biospace.com/
CNSP | News | $0.21 5.48% 0.95% 120K
|
Health Technology
|
| O: 5.82%
H: 7.57%
C: -7.32%
berubicin treatment pharmaceuticals glioblastoma study
Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer
Published: 2023-06-13 (Crawled : 12:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.83%
H: 7.38%
C: 6.11%
pharmaceuticals research
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results and Provides an Update on Clinical Development Programs
Published: 2021-03-01 (Crawled : 12:00) - globenewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.61%
H: 7.06%
C: 2.95%
financial results results
Reata Pharmaceuticals, Inc. Submits NDA for Company’s Lead Program: Bardoxolone in Alport Syndrome
Published: 2021-03-01 (Crawled : 12:00) - globenewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.61%
H: 7.06%
C: 2.95%
syndros program
CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-05-25 (Crawled : 20:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.18%
H: 0.79%
C: -2.78%
CNSP | News | $0.21 5.48% 0.95% 120K
|
Health Technology
|
| O: -4.52%
H: 6.84%
C: 4.74%
berubicin treatment pharmaceuticals glioblastoma study
DOCU INVESTOR NEWS: ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages DocuSign, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - DOCU
Published: 2022-01-30 (Crawled : 20:20) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 1.0%
H: 13.68%
C: 11.81%
DOCU | $56.71 1.56% 1.6% 1.3M
|
Technology Services
|
| O: 0.82%
H: 6.49%
C: 6.36%
deadline
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.